Connection

Kit Simpson to Markov Chains

Back to Details
This is a "connection" page, showing publications Kit Simpson has written about Markov Chains.
Kit Simpson
Connection Strength
1.594
Markov Chains
  1. Comparison of Markov model and discrete-event simulation techniques for HIV. Pharmacoeconomics. 2009; 27(2):159-65.
    View in: PubMed
    Score: 0.305
  2. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest. 2003 Dec; 124(6):2087-92.
    View in: PubMed
    Score: 0.214
  3. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates. Am J Manag Care. 1998 Jul; 4(7):1004-12.
    View in: PubMed
    Score: 0.147
  4. A cost-effectiveness analysis of anal cancer screening in HIV-positive women. J Low Genit Tract Dis. 2012 Jul; 16(3):275-80.
    View in: PubMed
    Score: 0.097
  5. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-na?ve and -experienced United Kingdom patients in 2011. J Med Econ. 2012; 15(4):796-806.
    View in: PubMed
    Score: 0.097
  6. Economic analysis of secondary trial data. Prog Cardiovasc Dis. 2012 Jan-Feb; 54(4):351-6.
    View in: PubMed
    Score: 0.094
  7. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya. Value Health. 2011 Dec; 14(8):1048-54.
    View in: PubMed
    Score: 0.093
  8. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis. Adv Ther. 2009 Mar; 26(3):346-68.
    View in: PubMed
    Score: 0.077
  9. Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study. Adv Ther. 2009 Feb; 26(2):185-93.
    View in: PubMed
    Score: 0.077
  10. Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States. HIV Clin Trials. 2008 Jul-Aug; 9(4):225-37.
    View in: PubMed
    Score: 0.074
  11. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. Clin Drug Investig. 2007; 27(1):67-74.
    View in: PubMed
    Score: 0.066
  12. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US. Clin Drug Investig. 2007; 27(7):443-52.
    View in: PubMed
    Score: 0.066
  13. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain. Clin Drug Investig. 2007; 27(12):807-17.
    View in: PubMed
    Score: 0.066
  14. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials. 2004 Sep-Oct; 5(5):294-304.
    View in: PubMed
    Score: 0.056
  15. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-na?ve women of childbearing age. J Med Econ. 2014 Apr; 17(4):250-8.
    View in: PubMed
    Score: 0.027
  16. Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. Clin Drug Investig. 2009; 29(10):635-46.
    View in: PubMed
    Score: 0.019
  17. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease. Clin Drug Investig. 2008; 28(5):291-303.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.